Development of a real-time clinical decision support system upon the web mvc-based architecture for prostate cancer treatment

被引:14
作者
Lin, Hsueh-Chun [1 ]
Wu, Hsi-Chin [2 ]
Chang, Chih-Hung [3 ,4 ]
Li, Tsai-Chung [5 ,6 ]
Liang, Wen-Miin [5 ,6 ]
Wang, Jong-Yi Wang [7 ]
机构
[1] China Med Univ, Dept Hlth Risk Management, Sch Publ Hlth, Taichung 40402, Taiwan
[2] China Med Univ, Dept Med, Sch Med, Shenyang, Peoples R China
[3] China Med Univ, Buehler Ctr Aging Hlth & Soc, Feinberg Sch Med, Northwestern Univ,Grad Inst Biostat, Shenyang, Peoples R China
[4] China Med Univ, Dept Med, Feinberg Sch Med, Northwestern Univ,Grad Inst Biostat, Shenyang, Peoples R China
[5] China Med Univ, Grad Inst Biostat, Shenyang, Peoples R China
[6] China Med Univ, Ctr Biostat, Shenyang, Peoples R China
[7] China Med Univ, Dept Hlth Serv Adm, Sch Publ Hlth, Shenyang, Peoples R China
来源
BMC MEDICAL INFORMATICS AND DECISION MAKING | 2011年 / 11卷
关键词
PREDICT PATHOLOGICAL STAGE; RADICAL PROSTATECTOMY; RADIATION-THERAPY; GLEASON SCORE; ANTIGEN; MEN; PSA; PERFORMANCE; MANAGEMENT; UPDATE;
D O I
10.1186/1472-6947-11-16
中图分类号
R-058 [];
学科分类号
摘要
Background: A real-time clinical decision support system (RTCDSS) with interactive diagrams enables clinicians to instantly and efficiently track patients' clinical records (PCRs) and improve their quality of clinical care. We propose a RTCDSS to process online clinical informatics from multiple databases for clinical decision making in the treatment of prostate cancer based on Web Model-View-Controller (MVC) architecture, by which the system can easily be adapted to different diseases and applications. Methods: We designed a framework upon the Web MVC-based architecture in which the reusable and extractable models can be conveniently adapted to other hospital information systems and which allows for efficient database integration. Then, we determined the clinical variables of the prostate cancer treatment based on participating clinicians' opinions and developed a computational model to determine the pretreatment parameters. Furthermore, the components of the RTCDSS integrated PCRs and decision factors for real-time analysis to provide evidence-based diagrams upon the clinician-oriented interface for visualization of treatment guidance and health risk assessment. Results: The resulting system can improve quality of clinical treatment by allowing clinicians to concurrently analyze and evaluate the clinical markers of prostate cancer patients with instantaneous clinical data and evidence-based diagrams which can automatically identify pretreatment parameters. Moreover, the proposed RTCDSS can aid interactions between patients and clinicians. Conclusions: Our proposed framework supports online clinical informatics, evaluates treatment risks, offers interactive guidance, and provides real-time reference for decision making in the treatment of prostate cancer. The developed clinician-oriented interface can assist clinicians in conveniently presenting evidence-based information to patients and can be readily adapted to an existing hospital information system and be easily applied in other chronic diseases.
引用
收藏
页数:11
相关论文
共 39 条
  • [1] [Anonymous], 1989, Clinical aspects of prostate cancer
  • [2] White paper - Reducing the frequency of errors in medicine using information technology
    Bates, DW
    Cohen, M
    Leape, LL
    Overhage, JM
    Shabot, MM
    Sheridan, T
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2001, 8 (04) : 299 - 308
  • [3] PROSPECTIVE EVALUATION OF PROSTATE-SPECIFIC ANTIGEN DENSITY AND SYSTEMATIC BIOPSIES FOR EARLY DETECTION OF PROSTATIC-CARCINOMA
    BAZINET, M
    MESHREF, AW
    TRUDEL, C
    ARONSON, S
    PELOQUIN, F
    NACHABE, M
    BEGIN, LR
    ELHILALI, MM
    [J]. UROLOGY, 1994, 43 (01) : 44 - 51
  • [4] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE
    CARTER, HB
    PEARSON, JD
    METTER, J
    BRANT, LJ
    CHAN, DW
    ANDRES, R
    FOZARD, JL
    WALSH, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16): : 2215 - 2220
  • [5] CARTER HB, 2007, CAMPBELL WALSH UROLO, V3
  • [6] Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements
    Catalona, WJ
    Smith, DS
    Ornstein, DK
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18): : 1452 - 1455
  • [7] Chaudhuri S., 1997, SIGMOD Record, V26, P65, DOI 10.1145/248603.248616
  • [8] RESULTS OF CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER
    CHODAK, GW
    THISTED, RA
    GERBER, GS
    JOHANSSON, JE
    ADOLFSSON, J
    JONES, GW
    CHISHOLM, GD
    MOSKOVITZ, B
    LIVNE, PM
    WARNER, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) : 242 - 248
  • [9] Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy
    D'Amico, AV
    Renshaw, AA
    Sussman, B
    Chen, MH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04): : 440 - 447
  • [10] Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Weinstein, M
    Tomaszewski, JE
    Schultz, D
    Rhude, M
    Rocha, S
    Wein, A
    Richie, JP
    [J]. JOURNAL OF UROLOGY, 2001, 166 (06) : 2185 - 2188